← Back to Clinical Trials
Recruiting NCT06883409

NCT06883409 Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06883409
Status Recruiting
Phase
Sponsor Instituto Nacional de Cancerologia de Mexico
Condition Ovarian Neoplasms
Study Type INTERVENTIONAL
Enrollment 33 participants
Start Date 2022-05-19
Primary Completion 2024-06-14

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Interval Cytoreduction Surgery

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 33 participants in total. It began in 2022-05-19 with a primary completion date of 2024-06-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a study that aims to demonstrate the non-inferiority of minimally invasive surgery versus open surgery, as an approach for patients with advanced ovarian cancer who received neoadjuvant chemotherapy, giving them the benefits of laparoscopic surgery. This way they can continue with their complementary treatment.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of epithelial ovarian cancer (all subtypes of epithelial ovarian cancer) in stage III-IV * Partial and complete response to treatment with QTNA after 3-4 cycles, evaluated by PET-CT imaging study, patients that the functional unit decides to incorporate into the project. * Ca 125 which will have to be less than 200 * ECOG 0 to 2 without medical contraindication to perform surgery (≤ ASA 2 or ≤ Goldman 2). Exclusion Criteria: * Partial response with persistence of ascites or pleural effusion. * With unresectability criteria (multiple intrahepatic liver metastases, retroperitoneal lymph node conglomerates \>2cm above the renal lymph nodes, metastatic disease above the diaphragm, multiple intestinal involvement and mesentery retraction).

Contact & Investigator

Central Contact

David Isla Ortiz, MD, M. Cs.

✉ islasurgery@hotmail.com

📞 +52 55 1850 9654

Frequently Asked Questions

Who can join the NCT06883409 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 80 Years, studying Ovarian Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06883409 currently recruiting?

Yes, NCT06883409 is actively recruiting participants. Contact the research team at islasurgery@hotmail.com for enrollment information.

Where is the NCT06883409 trial being conducted?

This trial is being conducted at México, Mexico.

Who is sponsoring the NCT06883409 clinical trial?

NCT06883409 is sponsored by Instituto Nacional de Cancerologia de Mexico. The trial plans to enroll 33 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology